Oncology Discovery & Early Development
Discovery and Early Development: The Power of Strategic Alignment
It takes a special scientific mindset to participate in early drug development – to explore new compounds, study them in depth and critically evaluate their promise as therapeutic agents. Discovery scientists must efficiently test and critically evaluate many compounds, knowing full well that while many may be scientifically promising, not every project will come to fruition.
At Janssen, the ability for our discovery efforts to fulfill their potential is maximized by the close integration of our discovery teams with our world-class development and commercialization capabilities. These integrated teams are organized within Disease Area Strongholds – disease areas of intense focus where we are cultivating deep expertise and where all of our early- and late-stage research, development and commercialization capabilities are strategically aligned against common goals and objectives. (Learn more about Disease Area Strongholds.)
This approach enables us to fully leverage our advanced discovery platforms and technology portfolio against clearly defined medical needs, therapeutic pathways and targets.
Our discovery platforms include:
- Antibody-directed cytotoxicity
- Signaling kinases
- Tumor metabolism
- Epigenetics and protein processing
- Monoclonal antibodies
Our technology platforms include:
- Small molecule discovery
- Core antibody technologies and antibody conjugates
- Transformational biological protein platforms
- Cell therapy and regenerative medicine (cell therapy and combination products)
- Vaccines and immuno-therapies
Translating Science to the Real World
Our high level of integration and strategic alignment also ensure that deep expertise in target disease areas is cultivated across the multiple disciplines involved in successfully delivering a new therapy from laboratory bench to patient. Our goal is to achieve the full potential of translational medicine – to connect what we learn in the laboratory to deliver truly meaningful clinical benefit as rapidly as possible.
We have core strengths and infrastructure in discovery, development, manufacturing and monoclonal antibody technologies, and we are leaders in the development and use of new biologics platforms.
We know that no one company, no single academic institution, can solve the challenge of cancer. Through our research partnerships we are bringing together the best scientific minds in industry and academia – wherever they may be, inside or outside our company – to confront the cancer challenge.